FY2025 EPS Estimates for Ocugen Increased by Chardan Capital

Ocugen, Inc. (NASDAQ:OCGN) – Chardan Capital lifted their FY2025 EPS estimates for Ocugen in a research report issued on Monday, August 4th. Chardan Capital analyst D. Gataulin now anticipates that the company will earn ($0.24) per share for the year, up from their previous estimate of ($0.25). Chardan Capital has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Ocugen’s current full-year earnings is ($0.20) per share.

Separately, HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Ocugen in a research report on Tuesday, June 24th.

Ocugen Trading Up 4.4%

Shares of OCGN stock opened at $1.00 on Thursday. The company has a quick ratio of 2.60, a current ratio of 1.83 and a debt-to-equity ratio of 9.18. The firm has a market cap of $292.30 million, a P/E ratio of -5.00 and a beta of 3.84. The company has a 50 day moving average of $1.03 and a 200-day moving average of $0.81. Ocugen has a 12-month low of $0.52 and a 12-month high of $1.40.

Ocugen (NASDAQ:OCGN) last released its earnings results on Friday, August 1st. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. Ocugen had a negative net margin of 1,197.71% and a negative return on equity of 255.25%. The firm had revenue of $1.37 million for the quarter, compared to analysts’ expectations of $0.35 million.

Hedge Funds Weigh In On Ocugen

Large investors have recently modified their holdings of the business. Vanguard Personalized Indexing Management LLC lifted its stake in shares of Ocugen by 48.8% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 29,871 shares of the company’s stock valued at $29,000 after buying an additional 9,791 shares in the last quarter. Invesco Ltd. lifted its position in shares of Ocugen by 8.7% during the first quarter. Invesco Ltd. now owns 188,678 shares of the company’s stock worth $133,000 after acquiring an additional 15,125 shares in the last quarter. Baader Bank Aktiengesellschaft boosted its holdings in shares of Ocugen by 108.8% in the second quarter. Baader Bank Aktiengesellschaft now owns 38,142 shares of the company’s stock worth $37,000 after acquiring an additional 19,876 shares during the period. XTX Topco Ltd grew its position in shares of Ocugen by 8.5% in the fourth quarter. XTX Topco Ltd now owns 254,995 shares of the company’s stock valued at $205,000 after purchasing an additional 19,894 shares in the last quarter. Finally, Rhumbline Advisers grew its position in shares of Ocugen by 6.4% in the first quarter. Rhumbline Advisers now owns 345,130 shares of the company’s stock valued at $244,000 after purchasing an additional 20,655 shares in the last quarter. Hedge funds and other institutional investors own 10.27% of the company’s stock.

Ocugen Company Profile

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.